Want to join the conversation?
Biopharma company $GILD said 2 Phase 3 trials, Studies 108 and 110, evaluating once-daily TAF 25 mg in adults with HBeAg-negative and HBeAg-positive chronic HBV infection met their primary endpoints of non-inferiority versus Viread 300 mg. TAF also showed improved renal and bone lab safety parameters versus Viread.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.